Mba MBA - Verastem Founder Consultant
| VSTM Stock | USD 4.19 0.25 5.63% |
Insider
Mba MBA is Founder Consultant of Verastem
| Age | 70 |
| Address | 117 Kendrick Street, Needham, MA, United States, 02494 |
| Phone | 781 292 4200 |
| Web | https://www.verastem.com |
Verastem Management Efficiency
The company has return on total asset (ROA) of (0.4731) % which means that it has lost $0.4731 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3687) %, meaning that it created substantial loss on money invested by shareholders. Verastem's management efficiency ratios could be used to measure how well Verastem manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of December 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Verastem's Other Current Assets are very stable compared to the past year. As of the 22nd of December 2024, Non Current Assets Total is likely to grow to about 11.4 M, while Non Currrent Assets Other are likely to drop about 4.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark DVM | Fate Therapeutics | 63 | |
| Merdad Parsey | Arcus Biosciences | 58 | |
| RPh RPh | Karyopharm Therapeutics | 55 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Edward III | Fate Therapeutics | 48 | |
| Robert II | Arcus Biosciences | 51 | |
| Bernard JD | Sana Biotechnology | 69 | |
| Mr MS | Karyopharm Therapeutics | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| James JD | Karyopharm Therapeutics | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Jonathan Yingling | Arcus Biosciences | 55 | |
| Steven Kanner | Caribou Biosciences | 65 | |
| Prof MD | Hookipa Pharma | 80 | |
| Mansoor MD | Karyopharm Therapeutics | 63 | |
| Rachel Haurwitz | Caribou Biosciences | 38 | |
| Carolyn Tang | Arcus Biosciences | 41 | |
| Linda Higgins | Arcus Biosciences | N/A | |
Management Performance
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.47 |
Verastem Leadership Team
Elected by the shareholders, the Verastem's board of directors comprises two types of representatives: Verastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verastem. The board's role is to monitor Verastem's management team and ensure that shareholders' interests are well served. Verastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Pachter, Chief Officer | ||
| Michael Crowther, Chief Officer | ||
| Richard MBA, Founder Consultant | ||
| Sean Flynn, Gen VP | ||
| MD MSc, Head Strategy | ||
| Robert Weinberg, CoFounder Board | ||
| Daniel Calkins, Interim Officer | ||
| Lisa Buffington, Senior Advocacy | ||
| Michelle MD, CoFounder | ||
| Piyush Gupta, CoFounder | ||
| Nate Sanburn, Senior Engagement | ||
| John MD, Chief Officer | ||
| Daniel Paterson, CEO President | ||
| BPHARM RPh, CEO Director | ||
| Mba MBA, Founder Consultant | ||
| Colleen Mockbee, Global Development | ||
| Robert MBA, Senior Operations | ||
| Cathy Carew, Chief Officer | ||
| Erin Cox, Sr Communications |
Verastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (11.45) % | ||||
| Current Valuation | 136.12 M | ||||
| Shares Outstanding | 44.51 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 59.90 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 16.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share 0.331 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.37) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.